Advertisement
Research ArticleArticle

Triethylenethiophosphoramide Is a Specific Inhibitor of Cytochrome P450 2B6: Implications for Cyclophosphamide Metabolism

James M. Rae, Nadia V. Soukhova, David A. Flockhart and Zeruesenay Desta
Drug Metabolism and Disposition May 2002, 30 (5) 525-530; DOI: https://doi.org/10.1124/dmd.30.5.525

Abstract

Cytochrome P450 2B6 is a genetically polymorphic enzyme that is important in the metabolism of a number of clinically used drugs. This enzyme is not as well studied as other cytochrome P450 (P450) isoforms because of the lack of specific antibodies, probe drugs, and inhibitors. Although recent progress has been made toward specific antibodies and probe drugs, a specific enzyme inhibitor is still lacking. Studies suggest that CYP2B6 plays an important role in the 4-hydroxylation of cyclophosphamide and that this reaction can be inhibited by triethylenethiophosphoramide (thioTEPA). We therefore wished to test the hypothesis that thioTEPA is an inhibitor of CYP2B6. Using human liver microsomes (HLMs) and recombinant P450 enzymes, we demonstrated that thioTEPA is a potent and specific inhibitor of CYP2B6. Enzyme activity was reduced 78.1 ± 0.2% by 50 μM thioTEPA when CYP2B6 activity was measured by following the metabolism of 200 μM S-mephenytoin to nirvanol. thioTEPA did not significantly inhibit (<20% at 100 μM) the other isoforms tested (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). thioTEPA seems to be a potent noncompetitive inhibitor of CYP2B6, withKi values of 4.8 ± 0.3 and 6.2 ± 0.7 μM for HLMs and recombinant CYP2B6, respectively, values that are within the plasma concentration range of thioTEPA at therapeutic doses (1.1–18.6 μM). We conclude that thioTEPA is a potent and specific inhibitor of CYP2B6 and that this is the likely mechanism by which thioTEPA inhibits the activation of cyclophosphamide. Furthermore, thioTEPA may prove to be a valuable new tool for the study of this important drug-metabolizing enzyme.

Recent studies into the role that cytochrome P450 2B6 plays in drug elimination have shown that this enzyme is important for the metabolism of a number of clinically used drugs. The growing list of compounds identified as substrates of CYP2B6 include nevirapine (Erickson et al., 1999), S-mephobarbital (Kobayashi et al., 1999), artemisinin (Svensson and Ashton, 1999), bupropion (Faucette et al., 2000) and propofol (Court et al., 2001), ifosfamide (Huang et al., 2000), ketamine (Yanagihara et al., 2001), selegiline (Hidestrand et al., 2001), and methadone (Gerber and Rhodes, 2000). Despite this growing list, this enzyme remains one of the least studied P4503 isoforms. This is probably due to the lack of suitable in vitro and in vivo tools available to study this enzyme (Ekins et al., 1997). Although recent progress has been made with respect to a specific substrate probe (Faucette et al., 2000) and immunological inhibitors of CYP2B6 (Yang et al., 1998), a specific chemical inhibitor is still lacking.

The level of expression of CYP2B6 protein in the human liver has been controversial until recently, with some earlier articles showing that only a small proportion of livers (<25%) (Mimura et al., 1993;Edwards et al., 1998) contain protein, whereas other studies have shown a more extensive level of expression (up to 90%) (Gervot et al., 1999;Hanna et al., 2000). The differences in antibodies used for each study may well contribute to the different results reported. More recent studies used antibodies prepared against human protein and have shown that nearly all of the liver samples have detectable levels of CYP2B6 (Gervot et al., 1999). However, more than a 20-fold difference in the level of protein (ranging from 0.4 to 8 pmol/mg of protein) was observed (Gervot et al., 1999). This variability may be caused by differences in exposure to environmental factors that can induce or inhibit the expression of CYP2B6 or by genetic polymorphisms that alter the expression or catalytic activity of the enzyme.

CYP2B6 has been shown to catalyze the 4-hydroxylation of cyclophosphamide at a high rate in vitro (Roy et al., 1999); however, its contribution to this reaction in vivo remains unclear. Cyclophosphamide is the most widely used antitumor alkylating agent and is often used in combination chemotherapy regimens for the treatment of many malignancies (Teicher, 1997). It is a prodrug that requires metabolic activation by the P450 system to 4-hydroxycyclophosphamide (4-OHCP) before it exerts cytotoxicity (Colvin et al., 1973). This primary metabolite exists in equilibrium with its open-ring tautomer aldophosphamide, which enters cells and undergoes chemical decomposition to form phosphoramide mustard, a bifunctional DNA alkylator and the ultimate cytotoxic metabolite, and acrolein. The P450-mediated activation pathway may be diminished by genetic polymorphisms of the enzymes involved or by concurrent administration of inhibitor drugs, which may lead to reduced 4-OHCP formation and decreased anticancer efficacy. Indeed, clinical studies suggest that triethylenethiophosphoramide (thioTEPA) inhibits the conversion of cyclophosphamide to 4-OHCP, and it has been recommended that these two agents should not be given together (Huitema et al., 2000). It follows that thioTEPA may inhibit one or more of the P450 isoforms implicated in cyclophosphamide activation.

thioTEPA is a cell cycle-phase, nonspecific antineoplastic agent used in the treatment of breast, ovarian, and bladder carcinomas (Maanen et al., 2000). This drug was originally approved by the Food and Drug Administration (FDA) in 1959, but its dose-limiting toxicity (myelosuppression) limited its use until its use in preparative regimens before autologous bone-marrow and peripheral stem-cell transplantation was recognized. In this context, thioTEPA is frequently given in conjunction with cyclophosphamide in high-dose chemotherapy regimens (van der Wall et al., 1995).

In the present study, we used human liver microsomes (HLMs) and recombinant P450 enzymes to evaluate the inhibitory potency of thioTEPA on eight clinically relevant drug-metabolizing P450 enzymes in vitro.S-Mephenytoin N-demethylation to nirvanol was used as a substrate probe of CYP2B6 in this study, as we (Ko et al., 1998) and other authors (Heyn et al., 1996) have previously shown that this reaction is predominantly catalyzed by CYP2B6 at high substrate concentrations. Our goal was to identify which enzymes are inhibited by thioTEPA to test the hypothesis that thioTEPA is an inhibitor of CYP2B6. These studies may help identify the mechanism underlying the clinical interaction between thioTEPA and cyclophosphamide. In addition, thioTEPA may prove a valuable new tool for the study of this important drug-metabolizing enzyme.

Materials and Methods

Chemicals.

thioTEPA was purchased from U.S. Pharmacopeia Convention (Rockville, MD). Tolbutamide, phenacetin, acetaminophen, midazolam, dextromethorphan, chlorzoxazone, G6P, G6PDH, NADP, and the disodium salt of EDTA were purchased from Sigma Chemical Co. (St. Louis, MO). Nirvanol, S-mephenytoin, 4-hydroxy-S-mephenytoin, 6-hydroxychlorzoxazone, 4-hydroxymidazolam, and 4-methylhydroxytolbutamide were purchased from Ultrafine Chemicals (Manchester, UK). Dextrorphan was purchased from F. Hoffman-La Roche, Inc. (Nutley, NJ). N-(4-Hydroxyphenyl)butamide was kindly provided by John Strong (Division of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD). Other reagents were of HPLC grade.

HLMs and Recombinant Human P450s.

The HLMs used were prepared from human liver tissue that was medically unsuitable for liver transplantation and frozen at −80οC within 3 h of the cross-clamp time. The characteristics of liver donors, procedure for preparation of microsomal fractions, and their P450 contents have been described in detail elsewhere (Harris et al., 1994). The microsomal pellets were resuspended in a reaction buffer (0.1 M Na+ and K+ phosphate, 1.0 mM EDTA, and 5.0 mM MgCl2, pH 7.4) to a protein concentration of 10 mg/ml (stock) and were kept at −80οC until used. Protein concentrations were determined according to Pollard et al. (1978). Detailed protocols for the measurement of each P450 isoform activity using isoform-specific substrate reaction probes and their apparent kinetic parameters (Km andVmax values) have been described in previous studies from our group (Desta et al., 2001). Baculovirus insect cell-expressed human CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, and CYP3A4 were purchased from GENTEST (Woburn, MA) and stored at −80°C. Protein concentrations and P450 contents were as supplied by the manufacturer.

Inhibition of P450 by thioTEPA.

The inhibitory effects of thioTEPA on the activities of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 were tested in recombinant human P450 isoforms and HLMs using isoform specific substrate probes, as described in our previous publications (Ko et al., 1998; Desta et al., 2001). The reaction probes used were as follows: phenacetin O-deethylation for CYP1A2,S-mephenytoin N-demethylation to nirvanol for CYP2B6, tolbutamide 4-methylhydroxylation for CYP2C8 and CYP2C9,S-mephenytoin 4-hydroxylation for CYP2C19, dextromethorphanO-demethylation for CYP2D6, chlorzoxazone 6-hydroxylation for CYP2E1, and midazolam 4-hydroxylation for CYP3A. Using incubation conditions specific to each isoform that were linear for time and substrate and protein concentrations, as detailed in our previous publications (Ko et al., 1998; Desta et al., 2001), isoform-specific substrate probes were incubated in duplicate at 37°C with HLMs or recombinant P450 isoforms and an NADPH-generating system in the absence (control) or presence of varying concentrations of thioTEPA (0–100 μM). Unless specified, a 5-min preincubation was carried out before the reaction was initiated by adding HLMs or recombinant P450. Preliminary experiments were carried out by incubating a single isoform-specific substrate concentration around itsKm value with a single (50 μM) or range (0–100 μM) of thioTEPA concentrations. Incubation conditions and HPLC methods for measurement of each activity are validated and have been routinely used in our laboratory and details are described elsewhere (Ko et al., 1998; Desta et al., 2001). Concentrations of substrate probes were as follows: phenacetin (50 μM), tolbutamide (50 μM), S-mephenytoin (25 and 200 μM), dextromethorphan (25 μM), chlorzoxazone (25 μM), and midazolam (25 μM).

Computer simulation of the preliminary data thus obtained was then used to estimate the appropriate substrate and thioTEPA concentrations for Dixon plot analysis and the determination of exact inhibition constants (Ki values). Since our data showed a potent effect of thioTEPA on CYP2B6 activity alone, Dixon plots were constructed for this isoform only. S-Mephenytoin (50, 75, and 150 μM) was incubated for 90 min at 37°C with a range of thioTEPA concentrations (0–15 μM) in HLMs and recombinant human CYP2B6 in the presence of an NADPH-generating system, as described above.

thioTEPA is a tri-aziridino-phosphine that could undergo P450-mediated biotransformation to metabolites that may alkylate (inactivate) CYP2B6 and contribute to the overall inhibition. To test for the presence of mechanism-based inactivation of CYP2B6 by thioTEPA, HLMs and recombinant human CYP2B6 were preincubated with an NADPH-generation system with or without thioTEPA (5 μM) for 0, 5, 10, 20, and 30 min. The reaction was started by adding a substrate probe and then further incubated for 90 min. To avoid false-positive inhibitions that may result from loss of enzyme activity due to prolonged incubation, parallel control experiments were determined by preincubating HLMs and an NADP-generating system without thioTEPA before the reaction was initiated by the addition of S-mephenytoin and further incubated.

After termination of the incubation reactions with appropriate reagents, samples were centrifuged and injected into an HPLC system either directly or after extraction and reconstitution with the respective mobile phase. The concentrations of the metabolites and internal standards were measured by HPLC with UV or fluorescent detection specific for each assay. The rates of production of each metabolite from the substrate probes were quantified by using the ratio of the area under the curve (AUC) of the metabolite to the AUC of each internal standard using an appropriate standard curve. The rates of metabolite formation from substrate probes in the presence of thioTEPA were compared with controls in which the inhibitor was replaced with vehicle.

HPLC.

Instruments used for HPLC were controlled by a Waters (Milford, MA) Millennium 2010 chromatography manager and included a Waters model 510 or 600 HPLC pump, Waters 710B or 717 Autosampler, Waters 490 or 484 UV detector, and Spectrovision FD-300 Dual Mono-Chromator Fluorescence Detector (Groton Technology Inc., Concord, MA). Full chromatographic conditions for each assay have been described elsewhere (Ko et al., 1998; Desta et al., 2001).

Enzyme Assays.

In a previous study, we have shown that a relatively high concentration (200 μM) of S-mephenytoin can be used to probe for CYP2B6 activity (Ko et al., 1998). Therefore, CYP2B6-catalyzedS-mephenytoin N-demethylation was measured as described in our previous work (Ko et al., 1998). Assays for CYP2C19-catalyzed (S)-mephenytoin 4-hydroxylation, CYP2D6-catalyzed dextromethorphan O-demethylation, CYP3A-catalyzed midazolam 4-hydroxylation, CYP1A2-catalyzedO-deethylation of phenacetin, CYP2E1-catalyzed chlorzoxazone 6-hydroxylation, and CYP2C9- and CYP2C8 (recombinant)-mediated 4-methylhydroxylation of tolbutamide were describe in detail previously (Desta et al., 2001).

Data Analysis.

The reaction velocity of each substrate probe in the presence of thioTEPA was expressed as the percentage of the control velocity with no thioTEPA present. Approximate Kivalues were calculated from experiments that were conducted using single substrate and multiple thioTEPA concentrations with use of the following equation assuming competitive inhibition:%Inhibition=100×[I][I]+Ki×1+[S]Km where I is the thioTEPA concentration,Ki is the inhibitory constant,S is the substrate concentration, andKm is the substrate concentration at half of the maximum velocity (Vmax) of the reaction.

Estimates for kinetic parameters from this analysis were used to generate computer-simulated optimal concentrations of substrate and thioTEPA for the determination of Dixon plots. The inhibition data from Dixon plots were fitted to appropriate nonlinear regression models of enzyme inhibition, and accurate Kivalues were calculated (WinNonlin Version 3.1; Pharsight Corporation, Mountain View, CA). The Ki values obtained from visual inspection of the Dixon plots served as initial estimates for this determination. An appropriate model and mechanism of inhibition were decided graphically and from parameters of the model using the dispersion of residuals and standard errors of the parameter estimates.

Results

thioTEPA has been shown to inhibit the P450-mediated metabolism of cyclophosphamide to 4-OHCP in the clinical setting and in vitro using HLMs. These studies however, did not determine which cytochrome P450 enzymes were inhibited by this agent. Therefore, we tested the inhibitory effects of thioTEPA on the activity of eight clinically relevant P450 isoforms. In our initial experiments, we used HLMs to determine the effects of thioTEPA on the activity of P450 activity, as assessed by isoform-specific substrate reaction probes at their approximate Km value. thioTEPA (50 μM) inhibited CYP2B6 activity by 78.1 ± 0.2%, as determined by following the N-demethylation of S-mephenytoin (200 μM) to nirvanol in HLMs, but it had little effect (≤20%) on the microsomal activity of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A (Fig. 1A; shown as the mean of duplicates ± S.E. of the mean). Because some of the substrate probes might also be metabolized by other P450 isoforms, we tested the ability of thioTEPA to inhibit the activity of recombinant human P450s. These results were consistent with those shown in Fig. 1A in that thioTEPA (50 μM) inhibited the activity of recombinant human CYP2B6 by 42.5 ± 2.4% while having no major effect (≤15%) on the activity of recombinant human CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4 (Fig. 1B; shown as the mean ± S.D. of four determinations).

Figure 1
Figure 1

Inhibition of cytochrome P450 activity by 50 μM thioTEPA.

A, inhibition of cytochrome P450 activity in HLMs; B, inhibition of recombinant human cytochrome P450 enzyme activity. The activity of each isoform was measured by isoform-specific substrate reaction probes shown as the mean ± S.D. of four determinations (duplicate readings from two separate experiments).

A range of thioTEPA concentrations (0–100 μM) was used to generate inhibitory dose response curves in HLMs and in recombinant CYP2C8 and CYP2C9 preparations. The recombinant proteins were used since tolbutamide 4-methylhydroxylation is not specific for the individual isoforms. The results in Fig. 2 (shown as the mean of duplicates) show that thioTEPA is a potent and specific inhibitor of CYP2B6, with 5 μM drug inhibiting the activity of this enzyme by 51%. The effects seem to plateau around 50 μM, with 50 and 100 μM inhibiting the activity of CYP2B6 by 78 and 83% respectively. In addition, this figure shows that thioTEPA has little effect on the other cytochrome P450 isoforms tested at concentrations up to 100 μM.

Figure 2
Figure 2

Specificity of dose response for inhibition of cytochrome P450 enzymes by thioTEPA (0 to 100 μM) in HLMs and recombinant human CYP2C8 and CYP2C9.

The activity of each isoform was measured by isoform-specific substrate reaction probes at their approximate respectiveKm values: 50 μM for phenacetinO-deethylation (CYP1A2), 25 μM forS-mephenytoin 4-hydroxylation (CYP2C19), 25 μM for dextromethorphan O-demethylation (CYP2D6), 20 μM for midazolam 4-hydroxylation (CYP3A), 50 μM for tolbutamide 4-methylhydroxylation (CYP2C8 and CYP2C9), 25 μM for chlorzoxazone 6-hydroxylation (CYP2E1), and 200 μM for S-mephenytoinN-demethylation (CYP2B6). Data represent the mean of duplicates.

The inhibitory data on CYP2B6 were used to approximate the range ofS-mephenytoin and thioTEPA concentrations needed to construct Dixon plots for the inhibition of CYP2B6 by thioTEPA to allow, in turn, the calculation of inhibition constants (Ki values). Dixon plots were generated in both HLMs and recombinant CYP2B6, and the results were compared. The representative plots in Fig.3 show that very similar results were obtained. The mean Ki values derived from two different human liver microsomal preparations (4.8 ± 0.3 μM) were very similar to those obtained using recombinant CYP2B6 (6.2 ± 0.7 μM). This type of inhibition, based on visual inspection of the Dixon plots and analysis of the data by nonlinear regression analysis using WinNonlin, was consistent with noncompetitive inhibition.

Figure 3
Figure 3

Representative Dixon plots for the inhibition of CYP2B6-catalyzed S-mephenytoin N-demethylation to nirvanol by thioTEPA in HLMs (A) and in recombinant human CYP2B6 (B).

Each point represents the mean of duplicate determinations.

The data described above (Figs. 1-3) suggest that thioTEPA is a potent inhibitor of CYP2B6, with little or no effect on the activities of other P450s tested. To further understand the mechanism by which thioTEPA inhibits CYYP2B6 activity, thioTEPA was preincubated in the presence of an NADPH-generating system and microsomes from human liver or recombinant human CYP2B6 before initiating the reaction by the addition of S-mephenytoin. Figure4 demonstrates that indeed preincubation of thioTEPA (5 μM) with HLMs before the addition ofS-mephenytoin (200 μM) slightly increased the degree of CYP2B6 inhibition. thioTEPA inhibited CYP2B6 activity by ∼43% at a 30- versus 0-min preincubation and by ∼21% when corrected for the control incubation (without thioTEPA) at a 30-min incubation. The effect of preincubation on the ability of thioTEPA to inhibit CYP2B6 was minimal when recombinant enzymes were used. The small decrease in the activity of CYP2B6 versus the duration of preincubation (Fig. 4B) was not unique, as it also happens in the control (without thioTEPA).

Figure 4
Figure 4

Effect of preincubation on the inhibitory effect of thioTEPA (5 μM) on the activity of CYP2B6 in HLMs (A) and recombinant CYP2B6 (B).

HLMs or recombinant human CYP2B6 were preincubated (0–30 min) in the presence of an NADPH-generating system without (controls) or with 5 μM thioTEPA before the reactions were initiated with the addition ofS-mephenytoin (200 μM) and further incubated for 90 min at 37°C. The effect of preincubation (percentage) in the controls and thioTEPA incubations was calculated by dividing the velocity at each specific preincubation time by the velocity at a preincubation time of zero. Each data point represents measurement of duplicate incubates.

Discussion

The metabolism of cyclophosphamide is complex and shows a great deal of interpatient variability (Moore et al., 1994), thus confounding the desire of prescribers to provide predictable consistent treatment. This variability in metabolism may account for some of the differences seen in response and toxicity, and it is therefore possible that drug interactions that alter metabolism may change cyclophosphamide effects. The data that we present here provide a possible mechanism for the clinical drug interaction between cyclophosphamide and thioTEPA and show that thioTEPA is a potent and specific inhibitor of CYP2B6.

Anderson et al. (1996) investigated a possible drug-drug interaction between thioTEPA and cyclophosphamide by measuring the pharmacokinetics of cyclophosphamide and 4-OHCP in patients before and during coadministration of thioTEPA. Their results showed that the AUC for cyclophosphamide was 1.4-fold higher and that the AUC for 4-OHCP was 22% lower when cyclophosphamide was coadministered with thioTEPA compared with cyclophosphamide given alone. These authors further tested the inhibitory effects of thioTEPA in vitro using HLMs. Their results show that thioTEPA inhibits the microsomal-mediated metabolism of cyclophosphamide to 4-OHCP in a concentration-dependent manner, with IC50 values ranging from 1.4 to 41 μM. In addition, they showed that total microsomal cyclophosphamide 4-hydroxylation activity was inhibited by 50 to 80% depending upon the microsomes used. They postulated that the observed differences in inhibition might reflect differential inhibition of P450 isoforms by thioTEPA. However, they did not test for inhibition of specific P450 enzymes. Our results suggest that CYP2B6 was the only enzyme inhibited in their HLM assays and, therefore, that CYP2B6 was probably responsible for more than 50% of 4-OHCP production.

A clinical drug-drug interaction between thioTEPA and cyclophosphamide was definitively shown in a study by Huitema et al. (2000), who altered the sequence of thioTEPA administration. When given 1 h before cyclophosphamide, the Cmax and AUC of 4-OHCP were decreased by 62 and 26%, respectively, compared with their values when thioTEPA was administered 1 h after cyclophosphamide. Since our data suggest that thioTEPA specifically inhibits CYP2B6, with no appreciable effect on other P450 isoforms, it is likely that this enzyme plays an important role in the activation of cyclophosphamide in vivo. Evidence in support of this hypothesis includes the range of theKi values that we determined for the inhibition of CYP2B6 in HLMs (Ki, 4.8 ± 0.3 μM) and recombinant CYP2B6 (Ki, 6.2 ± 0.7 μM), which are within the range of therapeutic concentrations reported for thioTEPA (1.1–18.6 μM) during a 4-day intravenous infusion at a dose of 400 to 800 mg/m2 (Kennedy et al., 1995). Concentrations of thioTEPA that were as high as 100 μM did not alter the activity of the other P450 enzymes that seem to be involved in cyclophosphamide 4-hydroxylation. This suggests that CYP2B6 is the only clinically relevant P450 inhibited by thioTEPA at therapeutic plasma concentrations. Although we cannot definitively rule out the possibility that thioTEPA alters the activity of other P450 or non-P450 enzymes in vivo, our study did include the principal cytochrome P450 enzymes known to be responsible for cyclophosphamide hydroxylation, and it would seem unlikely that other enzymes play a major role.

It is interesting to note that the type of inhibition of CYP2B6 by thioTEPA is noncompetitive. thioTEPA is tris-aziridino-phosphine and could be metabolized by cytochrome P450 enzymes to an alkylating agent that could alkylate P450s. This phenomenon in turn may account for the noncompetitive nature we observed but would also result in time-dependent inhibition. Although the specific P450 isoform involved in the metabolism of thioTEPA in humans is not yet clear, evidence from animal studies suggest that thioTEPA is metabolized by P450s, notably CYP2B1 and CYP2C11 (Chang et al., 1995). There is also evidence that thioTEPA is a suicide inhibitor of certain rat P450s (Ng and Waxman, 1990). We have noted that the ability of thioTEPA to inhibit CYP2B6 was increased with the duration of preincubation of thioTEPA with an NADPH-generating system and HLMs before the addition ofS-mephenytoin. Although, the effect was modest, it does suggest that inhibition of CYP2B6 by thioTEPA is time-dependent. The possibility that thioTEPA alkylates CYP2B6 and thus may contribute to the noncompetitive inhibition observed was not directly tested and cannot be ruled out.

Besides cyclophosphamide, recent articles have suggested that CYP2B6 plays an important role in the metabolism of a number of other clinically used drugs. The variability in the pharmacokinetics of these agents may be related to the variability in the level of CYP2B6 expression. CYP2B6 is highly inducible by drugs, such as phenobarbital, and this may explain differences in its level of expression, and recent advances in the underlying biochemical mechanisms of induction have elucidated this (Honkakoski et al., 1998). These advances may help identify other environmental factors that affect CYP2B6 expression. In addition, genetic polymorphisms in CYP2B6 may affect its activity. One such polymorphism was described in a Japanese population (Ariyoshi et al., 2001). This polymorphism has an allelic frequency of 20% and is the result of a G to T nucleotide change at position 516. The variant allele exhibits increased catalytic activity forO-deethylation of 7-ethoxycoumarin in vitro, whereas its in vivo effect has yet to be determined. Another study by Lang et al. (2001), found nine polymorphisms in the CYP2B6 gene, five of which resulted in amino acid substitutions. The authors showed that a polymorphism in exon 9 was associated with significantly reduced CYP2B6 protein expression and S-mephenytoinN-demethylase activity in human liver specimens. Taken together, these studies suggest an underlying genetic component to the variability in CYP2B6 activity.

Our data demonstrate for the first time that thioTEPA is a potent and specific inhibitor of CYP2B6. These findings have important implications. First, the specificity of thioTEPA can be used as a tool to study the activity of CYP2B6 in vitro so that we may be able to further characterize the role of this enzyme in human drug metabolism. Second, the clinical interaction of cyclophosphamide and thioTEPA documented in the literature seems to be mediated by the ability of thioTEPA to inhibit CYP2B6 and underlines the role of CYP2B6 in cyclophosphamide activation in vivo. Finally, thioTEPA is likely to inhibit the metabolism of agents beyond cyclophosphamide and caution should be used during coadministration with other CYP2B6 substrate drugs.

Footnotes

  • ↵1 Current address: Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109.

  • ↵2 Currently address: Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202.

  • This work was funded in part by National Institute of General Medical Sciences (Bethesda, MD) Grants GM61373 (UO1), GM56898 (RO1), and GM08386 (T32).

  • Abbreviations used are::
    P450
    cytochrome P450
    4-OHCP
    4-hydroxycyclophosphamide
    thioTEPA
    triethylenethiophosphoramide
    HLMs
    human liver microsomes
    HPLC
    high-pressure liquid chromatography
    AUC
    area under the curve
    • Received October 29, 2001.
    • Accepted January 25, 2002.

References

  1. ↵
    1. Anderson LW,
    2. Chen TL,
    3. Colvin OM,
    4. Grochow LB,
    5. Collins JM,
    6. Kennedy MJ,
    7. Strong JM
    (1996) Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res 2:1481–1487.
    OpenUrlAbstract
  2. ↵
    1. Ariyoshi N,
    2. Miyazaki M,
    3. Toide K,
    4. Sawamura Y,
    5. Kamataki T
    (2001) A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 281:1256–1260.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Chang TK,
    2. Chen G,
    3. Waxman DJ
    (1995) Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. J Pharmacol Exp Ther 274:270–275.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Colvin M,
    2. Padgett CA,
    3. Fenselau C
    (1973) A biologically active metabolite of cyclophosphamide. Cancer Res 33:915–918.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Court MH,
    2. Duan SX,
    3. Hesse LM,
    4. Venkatakrishnan K,
    5. Greenblatt DJ
    (2001) Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes anesthesiology. Anesthesiology 94:110–119.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Desta Z,
    2. Soukhova NV,
    3. Flockhart DA
    (2001) Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 45:382–392.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Edwards RJ,
    2. Adams DA,
    3. Watts PS,
    4. Davies DS,
    5. Boobis AR
    (1998) Development of a comprehensive panel of antibodies against the major xenobiotic metabolizing forms of cytochrome P450 in humans. Biochem Pharmacol 56:377–387.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ekins S,
    2. VandenBranden M,
    3. Ring BJ,
    4. Wrighton SA
    (1997) Examination of purported probes of human CYP2B6. Pharmacogenetics 7:165–179.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Erickson DA,
    2. Mather G,
    3. Trager WF,
    4. Levy RH,
    5. Keirns JJ
    (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 27:1488–1495.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Faucette SR,
    2. Hawke RL,
    3. LeCluyse EL,
    4. Shord SS,
    5. Yan B,
    6. Laethem RM,
    7. Lindley CM
    (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–1230.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Gerber JG,
    2. Rhodes JG
    (2000) Cytochrome P450 2B6 (CYP2B6) metabolizes methadone (M) preferentially and stereospecifically. An explanation of drug interactions with antiretroviral drugs, 1st International Workshop on Clinical Pharmacology of HIV Therapy; 2000 March 30–31; Noordwijk, The Netherlands, Abstract 2.2.
  12. ↵
    1. Gervot L,
    2. Rochat B,
    3. Gautier JC,
    4. Bohnenstengel F,
    5. Kroemer H,
    6. Berardinis V,
    7. Martin H,
    8. Beaune P,
    9. de Waziers I
    (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306.
    OpenUrlPubMed
  13. ↵
    1. Hanna IH,
    2. Reed JR,
    3. Guengerich FP,
    4. Hollenberg PF
    (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys 376:206–216.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Harris JW,
    2. Rahman A,
    3. Kim BY,
    4. Guengerich FP,
    5. Collins JM
    (1994) Metabolism by Taxol and human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026–4035.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Heyn H,
    2. White RB,
    3. Stevens JC
    (1996) Catalytic role of cytochrome P450 2B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948–954.
    OpenUrlAbstract
  16. ↵
    1. Hidestrand M,
    2. Oscarson M,
    3. Salonen JS,
    4. Nyman L,
    5. Pelkonen O,
    6. Turpeinen M,
    7. Ingelman-Sundberg M
    (2001) Cyp2b6 and cyp2c19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 29:1480–1484.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Honkakoski P,
    2. Zelko I,
    3. Sueyoshi T,
    4. Negishi M
    (1998) The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 18:5652–5658.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Huang Z,
    2. Roy P,
    3. Waxman DJ
    (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59:961–972.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Huitema AD,
    2. Kerbusch T,
    3. Tibben MM,
    4. Rodenhuis S,
    5. Beijnen JH
    (2000) Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother Pharmacol 46:119–127.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Kennedy MJ,
    2. Armstrong DK,
    3. Huelskamp AM,
    4. Ohly K,
    5. Clarke BV,
    6. Colvin OM,
    7. Grochow LB,
    8. Chen TL,
    9. Davidson NE
    (1995) Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol 13:1136–1143.
    OpenUrlAbstract
  21. ↵
    1. Ko JW,
    2. Desta Z,
    3. Flockhart DA
    (1998) Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab Dispos 26:775–778.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Kobayashi K,
    2. Abe S,
    3. Nakajima M,
    4. Shimada N,
    5. Tani M,
    6. Chiba K,
    7. Yamamoto T
    (1999) Role of human CYP2B6 in S-mephobarbital N-demethylation. Drug Metab Dispos 27:1429–1433.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Lang T,
    2. Klein K,
    3. Fischer J,
    4. Nussler AK,
    5. Neuhaus P,
    6. Hofmann U,
    7. Eichelbaum M,
    8. Schwab M,
    9. Zanger UM
    (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399–415.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Maanen MJ,
    2. Smeets CJ,
    3. Beijnen JH
    (2000) Chemistry, pharmacology and pharmacokinetics of N,N′,N"-triethylenethiophosphoramide (thioTEPA). Cancer Treat Rev 26:257–268.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Mimura M,
    2. Baba T,
    3. Yamazaki H,
    4. Ohmori S,
    5. Inui Y,
    6. Gonzalez FJ,
    7. Guengerich FP,
    8. Shimada T
    (1993) Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos 21:1048–1056.
    OpenUrlAbstract
  26. ↵
    1. Moore MJ,
    2. Erlichman C,
    3. Thiessen JJ,
    4. Bunting PS,
    5. Hardy R,
    6. Kerr I,
    7. Soldin S
    (1994) Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother Pharmacol 33:472–476.
    OpenUrlPubMed
  27. ↵
    1. Ng SF,
    2. Waxman DJ
    (1990) Biotransformation of N,N′,N"-triethylenethiophosphoramide: oxidative desulfurization to yield N,N′,N′′-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase. Cancer Res 50:464–471.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Pollard HB,
    2. Menard R,
    3. Brandt HA,
    4. Pazoles CJ,
    5. Creutz CE,
    6. Ramu A
    (1978) Application of Bradford's protein assay to adrenal gland subcellular fractions. Anal Biochem 86:761–763.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Roy P,
    2. Yu LJ,
    3. Crespi CL,
    4. Waxman DJ
    (1999) Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655–666.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Svensson US,
    2. Ashton M
    (1999) Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 48:528–535.
    OpenUrlCrossRefPubMed
  31. ↵
    1. DeVita VT,
    2. Hellman S,
    3. Rosenburg SA
    1. Teicher BA
    (1997) Antitumor Alkylating Agents. in Cancer Principles and Practice of Oncology, eds DeVita VT, Hellman S, Rosenburg SA (Lippincott-Raven, New York), pp 405–418.
  32. ↵
    1. van der Wall E,
    2. Beijnen JH,
    3. Rodenhuis S
    (1995) High-dose chemotherapy regimens for solid tumors. Cancer Treat Rev 21:105–132.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Yanagihara Y,
    2. Kariya S,
    3. Ohtani M,
    4. Uchino K,
    5. Aoyama T,
    6. Yamamura Y,
    7. Iga T
    (2001) Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 29:887–890.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Yang TJ,
    2. Krausz KW,
    3. Shou M,
    4. Yang SK,
    5. Buters JT,
    6. Gonzalez FJ,
    7. Gelboin HV
    (1998) Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol 55:1633–1640.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Triethylenethiophosphoramide Is a Specific Inhibitor of Cytochrome P450 2B6: Implications for Cyclophosphamide Metabolism

James M. Rae, Nadia V. Soukhova, David A. Flockhart and Zeruesenay Desta
Drug Metabolism and Disposition May 1, 2002, 30 (5) 525-530; DOI: https://doi.org/10.1124/dmd.30.5.525
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement